Cancer prevention trial of a synergistic mixture of green tea concentrate plus Capsicum (CAPSOL-T) in a random population of subjects ages 40-84

Abstract

BackgroundExperts agree that one of the more promising strategies in cancer management is early detection coupled with early intervention. In this study, we evaluated an early cancer detection strategy of cancer presence based on serum levels of the cancer-specific transcript variants of ENOX2 in serum coupled with an ENOX2-targeted nutraceutical preparation of green tea concentrate plus Capsicum (Capsol-T®) as a strategy of Curative Prevention® involving early detection coupled with early intervention in early stage cancer when in its most susceptible and manageable stages.Experimental designOne hundred ten (110) subjects were tested for cancer presence using the ONCOblot® Tissue of Origin 2-D gel/western blot protocol for detection of serum presence of transcript variants of the ENOX2 protein. Subjects testing positive for ENOX2 received 350 mg of Capsol-T® in capsule form every 4 h including during the night for periods of at least 3 to 6 months or longer after which they were again tested for ENOX2 presence using the ONCOblot® Tissue of Origin Cancer Test protocol.ResultsOf the 110 subjects, both male and female, ages 40 to 84, with no evidence of clinical symptoms of cancer, 40% were positive for ENOX2 presence in the ONCOblot® Tissue of Origin Cancer Test. After completion of 3 to 17 months of Capsol-T® use, 94% of subjects subsequently tested negative for ENOX2 presence.ConclusionsOral Capsol-T® is well tolerated and, for ENOX2 presence in serum in the absence of clinical cancer symptoms, is consistently effective in reducing the serum ENOX2 levels to below detectable limits.

ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms

“…AF207881. The limit of detection of the ONCOblot assay is approximately 100 femtomoles of an ENOX2 protein [ 11 ].…”

“…Identification of cancer presence by detecting ENOX2 transcript variants produces a low incidence of both false positives and false negatives (>1 % for subjects with clinically confirmed cancers), as they are molecular signature molecules produced specifically by cancer cells and are absent from non-cancer cells [ 10 ]. The predictive correlation between ONCOblot findings and the onset of cancer is based on findings that support ENOX2 as a marker of cancer presence [ 11 ].…”

Polyphenols as Modulator of Oxidative Stress in Cancer Disease: New Therapeutic Strategies

“…Accumulating evidence shows that ROS levels in tumour cells are crucial for designing advanced therapies and future challenge in anticancer treatments. To this purpose, increasing knowledge from epidemiological and experimental data supports the bright future of natural polyphenols as anticancer tools [ 191 – 194 ] ( Figure 2 ). The complex balance among cell proliferation, apoptosis, and senescence induced by polyphenols could be exploited therapeutically to improve the efficacy of conventional cancer treatment and to develop new antitumour strategies ( Table 1 ).…”

Cancer of the Pancreas (CaP) New Thoughts, New Approaches for the New Year

“…Nearly all were small intraductal papillary mucinous lesions, and most were followed and observed [9,10]. The few resected lesions were benign,or "premalignant", with atypia, dysplasia, and high grade PanIN .The National Familial Pancreas Tumor Registry follows first degree asymptomatic relatives when 3 or more family members have/ had CaP, and has detected 56 relatives with pancreatic cancer, almost all with metastatic disease [11][12][13][14][15][16][17].…”